

SUPPLEMENTAL FIGURE LEGENDS




Figure S1: Analysis of TPO levels of 42 platelet-antibody positive patients and of 178 platelet-antibody negative patients. Out of the 42 platelet-antibody positive patients 36 patients had normal TPO levels and six patients had elevated TPO levels. Of the patients that tested negative for platelet-antibodies: 138 patients had normal TPO levels and 40 patients had elevated TPO levels.

SUPPLEMENTAL TABLES

Supplemental Table S1: Details HIT-like VITT patients tested for platelet-antibodies. Patients who were considered HIT-like VITT patients (with thrombocytopenia and thrombosis) and were tested for the presence of platelet-antibodies in the indirect MAIPA. *Patient 2 was tested at 20 days after vaccination but was not considered probable VITT after a negative FcγRIIa-dependent PIPAA at 22 days after vaccination, the second FcγRIIa-dependent PIPAA at 42 days after vaccination was positive.

Patient	Sex (M/F)	Age	Vaccine	Dose	Days since vaccination	anti-PF4 ELISA (OD)	FcγRIIa-dependent PIPAA(+/-)	Platelet count at admission	Site thrombosis	Indirect MAIPA (+/-)	TPO levels
1	M	67	ChAdOx1 nCov-19	-	12	>3.0	+	<100	CVST	-	28
2*	F	32	ChAdOx1 nCov-19	-	42	2.1	+	<100	Mesenteric thrombosis	-	24
3	F	75	ChAdOx1 nCov-19	-	-	>3.0	+	<100	DVT	-	67 (elevated)
4	M	64	ChAdOx1 nCov-19	1	9	>3.0	+	<100	Intracranial	-	115 (elevated)
5	M	61	ChAdOx1 nCov-19	-	-	>3.0	+	<100	Multiple	-	14
6	F	28	Ad26.COVS.S	1	11	2.24	+	<100	CVST	-	22
7	F	53	Ad26.COVS.S	1	-	>3.0	+	<100	Other	-	15

Supplemental Table S2: Results from anti-PF4 IgG ELISA, FcγRIIIa-dependent PIPAA and indirect MAIPA. * considered HIT-like VITT patients. † tested positive in both the anti-PF4 IgG ELISA and PIPAA but did not have thrombocytopenia and thrombosis or clinical characteristics were unknown.

Clinical characteristics	anti-PF4 IgG ELISA	FcγRIIIa-dependent PIPAA (pos/neg)	Indirect MAIPA (pos/neg)
Thrombocytopenia only (n=119)	Neg (n=111)	Neg (n=108)	Neg (n=79)
			Pos (n=29)
		Pos (n=3)	Neg (n=1)
			Pos (n=2)
	Pos (n=8)	Neg (n=5)	Neg (n=5)
Pos (n=3)†		Neg (n=3)	
Thrombosis only (n=39)	Neg (n=38)	Neg (n=36)	Neg (n=33)
			Pos (n=3)
		Pos (n=2)	Neg (n=1)
	Pos (n=1)		
Pos (n=1)	Pos (n=1)†	Neg (n=1)	
Thrombocytopenia and thrombosis (n=32)	Neg (n=22)	Neg (n=21)	Neg (n=20)
			Pos (n=1)
		Pos (n=1)	Pos (n=1)
	Pos (n=10)	Neg (n=3)	Neg (n=2)
		Pos (n=7)*	Pos (n=1)
Clinical characteristics unknown (n=23)	Neg (n=22)	Neg (n=22)	Neg (n=18)
			Pos (n=4)
			Pos (n=1)
No thrombocytopenia, no thrombosis (n=19)	Neg (n=19)	Neg (n=19)	Neg (n=18)
			Pos (n=1)

Supplemental Table S3: Requests for ITP diagnostic reference testing. Increase in platelet-autoantibody testing and positive tests after implementation of the ITP guidelines in June 2020 and a further increase in testing and positive tests since the start of the vaccination on January 8, 2021.

Time period	Patients tested positive for platelet-autoantibodies of total number of tests performed N(%)
July-December 2019	132 (42.6)
January-June 2020	128 (46.9)
July – December 2020	166 (38.1)
January – June 2021	240 (44.6)
July-December 2021	228 (42.0)
January -June 2022	273 (48.3)